| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Chapter Links... |
 Link to Cancer Drug Fund List |
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
| 08.01.05 |
Amsacrine |
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
| 08.01.05 |
Bevacizumab |
|
|
| 08.01.05 |
Bexarotene |
|
|
| 08.01.05 |
Bortezomib |
|
|
| 08.01.05 |
Cetuximab |
|
|
| 08.01.05 |
Crisantaspase |
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
| 08.01.05 |
Erlotinib |
|
|
| 08.01.05 |
Hydroxycarbamide |
|
|
| 08.01.05 |
Imatinab |
|
|
| 08.01.05 |
Mitotane |
|
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib (Giotrif ®)
|
Formulary
 
|
For use in line with NICE TA310:
Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:
the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
the person has not previously had an EGFR-TK inhibitor and
the manufacturer provides afatinib with the discount agreed in the patient access scheme.
Commissioned by NHSE
|
NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Dasatinib (Sprycel®)
|
Formulary
|
In line with NICE TA425 and NICE TA426
NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.
NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes
Commissioned by NHSE
|
Link to CDF secure application site
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Erlotinib (Tarceva®)
|
Formulary
|
First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer in line with NICE TA258
Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) in line with NICE TA374
Commissioned by NHSE
|
NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Everolimus (Afinitor®)
|
Formulary
|
Treating advanced breast cancer in combination with exemestane after endocrine therapy in line with NICE TA421
Commissioned by NHSE
|
NICE TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
|
Gefitinib (Iressa®)
|
Formulary
|
In line With NICE TA192 and NICE TA374
Commissioned by NHSE
|
NICE TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Imatinib (Gilvec®)
|
Formulary
|
In line with NICE TA86 & NICE TA326:
Adjuvant treatment of gastro-intestinal stromal tumours (GIST), in patients considered at high risk of relapse (based on risk criteria or mutation analysis), for up to 3 years.
NICE TA209 specifies doses above 400mg not recommended.
NICE TA70 & TA426:
Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.
Commissioned by NHSE
|
NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
NICE TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
NICE TA70 Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link to CDF secure application site
|
Nilotinib (Tasigna®)
|
Formulary
|
In line with NICE TA425 and TA426.
NICE TA426:
Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes
(NHSE is the responsible commissioner)
NICE TA425:
Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
•they cannot have imatinib, or their disease is imatinib-resistant and
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes.
Commissioned by NHSE
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Palbociclib (Ibrance®)
|
Formulary
|
With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA495
With fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer in line with NICE TA619
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Regorafenib (Stivarga®)
|
Formulary
|
For previously treated unresectable or metastatic gastrointestinal stromal tumours in line with NICE TA488
For previously treated advanced hepatocellular carcinoma in line with NICE TA555
|
Link to CDF secure application site
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
|
Ribociclib (Kisqali®)
|
Formulary
|
With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE TA496.
Commissioned by NHSE
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
Sorafenib (Nexavar®)
|
Formulary
|
Commissioned by NHSE
|
Link to CDF secure application site
|
Sunitinib (Sutent®)
|
Formulary
|
Advanced and/or metastatic renal cell carcinoma in line with NICE TA169
Gastrointestinal stromal tumours in line with NICE TA179 .
Commissioned by NHSE
|
Link to CDF secure application site
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA169: Renal cell carcinoma - sunitinib
|
Temsirolimus (Torisel®)
|
Formulary
|
|
Link to CDF secure application site
|
Tivozanib (Fotivda®)
|
Formulary
|
For treating advanced renal cell carcinoma, in line with NICE TA512
|
Link to CDF secure application site
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
|
| 08.01.05 |
Taxanes |
|
|
| 08.01.05 |
Topoisimerase I inhibitors |
|
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Trastuzumab |
|
|
| 08.01.05 |
Tretinoin |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
|
|
|
